The role of CD40 in the pathogenesis and treatment of cancer

Aristides Eliopoulos, Lawrence Young

Research output: Contribution to journalReview article

75 Citations (Scopus)


CD40 is a tumour necrosis factor receptor family member that is overexpressed in a broad range of leukaemias, lymphomas and carcinomas, and could contribute to their development. Recent experimental and clinical observations suggest that the CD40 pathway can be exploited for the treatment of malignancy. The mechanisms by which CD40 activation exerts anti-tumour effects include inhibition of tumour cell proliferation, sensitisation to other anti-cancer agents, including cytotoxic drugs, upregulation of immune processing and presentation within the malignant cells, and stimulation of anti-tumour immune responses via activation of dendritic cells. Thus, the CD40 pathway provides an opportunity to muster different anti-cancer approaches in one therapy, and offers an attractive option for future clinical trials.
Original languageEnglish
Pages (from-to)360-367
Number of pages8
JournalCurrent Opinion in Pharmacology
Publication statusPublished - 1 Jan 2004


Dive into the research topics of 'The role of CD40 in the pathogenesis and treatment of cancer'. Together they form a unique fingerprint.

Cite this